1
|
Jensen M, Eickhoff MK, Persson F, Rossing P, Thiel S, Hansen SWK, Palarasah Y, Svenningsen P, Jensen BL. Effect of dapagliflozin on collectins and complement activation in plasma from patients with type 2 diabetes and albuminuria: Data from the DapKid cohort. Immunobiology 2024; 229:152797. [PMID: 38518448 DOI: 10.1016/j.imbio.2024.152797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2023] [Revised: 03/13/2024] [Accepted: 03/15/2024] [Indexed: 03/24/2024]
Abstract
BACKGROUND Sodium-glucose cotransporter 2 (SGLT- 2) inhibitors exert cardiovascular and kidney-protective effects in people with diabetes. Attenuation of inflammation could be important for systemic protection. The lectin pathway of complement system activation is linked to diabetic nephropathy. We hypothesized that SGLT-2 inhibitors lower the circulating level of pattern-recognition molecules of the lectin cascade and attenuate systemic complement activation. METHODS Analysis of paired plasma samples from the DapKid crossover intervention study where patients with type 2 diabetes mellitus (T2DM) and albuminuria were treated with dapagliflozin and placebo for 12 weeks (10 mg/day, n=36). ELISA was used to determine concentrations of collectin kidney 1 (CL-K1), collectin liver 1 (CL-L1), mannose-binding lectin (MBL), MBL-associated serine protease 2 (MASP-2), the anaphylatoxin complement factor 3a (C3a), the stable C3 split product C3dg and the membrane attack complex (sC5b-9). RESULTS As published before, dapagliflozin treatment lowered Hba1C from 74 (14.9) mmol/mol to 66 (13.9) mmol/mol (p<0.0001), and the urine albumin/creatinine ratio from 167.8 mg/g to 122.5 mg/g (p<0.0001). Plasma concentrations of CL-K1, CL-L1, MBL, and MASP-2 did not change significantly after dapagliflozin treatment (P>0.05) compared to placebo treatment. The plasma levels of C3a (P<0.05) and C3dg (P<0.01) increased slightly but significantly, 0.6 [0.2] units/mL and 76 [52] units/mL respectively, after dapagliflozin treatment. The C9-associated neoepitope in C5b-9 did not change in plasma concentration by dapagliflozin (P>0.05). CONCLUSION In patients with type 2 diabetes and albuminuria, SGLT-2 inhibition resulted in modest C3 activation in plasma, likely not driven by primary changes in circulating collectins and not resulting in changes in membrane attack complex. Based on systemic analyses, organ-specific local protective effects of gliflozins against complement activation cannot be excluded.
Collapse
Affiliation(s)
- Mia Jensen
- Unit of Cardiovascular and Renal Research, Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
| | | | | | - Peter Rossing
- Steno Diabetes Center Copenhagen, Herlev, Denmark; University of Copenhagen, Department of Clinical Medicine, Copenhagen, Denmark
| | - Steffen Thiel
- Department of Biomedicine, Aarhus University, Aarhus, Denmark
| | - Søren W K Hansen
- Unit for Cancer and Inflammation Research, Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark
| | - Yaseelan Palarasah
- Unit for Cancer and Inflammation Research, Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark
| | - Per Svenningsen
- Unit of Cardiovascular and Renal Research, Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark
| | - Boye L Jensen
- Unit of Cardiovascular and Renal Research, Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark
| |
Collapse
|
2
|
Bjerrum KB, Aagaard JB, Soucy JA, Kabiljagic AA, Skjoedt K, Graversen JH, Henriksen ML, Hansen SWK. Facile generation of monoclonal antibodies suitable for conjugation. J Immunol Methods 2020; 483:112807. [PMID: 32540393 DOI: 10.1016/j.jim.2020.112807] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2019] [Revised: 02/06/2020] [Accepted: 06/09/2020] [Indexed: 10/24/2022]
Abstract
Monoclonal antibodies (mAb) are unique tools in therapeutics and immunodiagnostics applications but many of these applications rely on conjugated mAbs. Whether conjugating drugs or tracers, the conjugation process, frequently taking advantage of primary amines on lysine residues, may affect the binding activity of the antibodies. Furthermore, due to the sticky nature of many mAbs, unfavorable interactions may become eminent, with the result of high background signals. The workload associated with producing mAbs, able to withstand conjugation, preserving stability and affinity and avoiding off-target interactions, is comprehensive and related with only incidental success. We designed a method, where uncloned hybridomas were pre-selected for secretion of mAbs with the above characteristics. Using human collectin K1 (CL-K1, alias CL-11, Colec11) as a model antigen, mAbs present in culture supernatant from uncloned hybridomas were immobilized on Protein A beads, followed by solid phase biotinylation and subsequent elution. ELISA was employed to compare the binding activity of conjugated vs. unconjugated mAbs, and furthermore for their application in combination with other antibodies. From a group of 96 uncloned hybridomas we accomplished in obtaining five suitable mAbs, among which, two mAbs were superior. The successful conjugation of the selected mAbs with fluorophores and subsequent applications in microscopy and flow cytometry were further demonstrated. In conclusion, pre-selection of uncloned hybridomas, by testing of their mAbs' ability to withstand conjugation with tracers or drugs, is a successful strategy to avoid a huge workload of cloning numerous hybridomas, in order to obtain conjugatable mAbs.
Collapse
Affiliation(s)
- K B Bjerrum
- Dept. of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, J.B. Winsloewsvej 25-2, 5000 Odense C, Denmark
| | - J B Aagaard
- Dept. of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, J.B. Winsloewsvej 25-2, 5000 Odense C, Denmark
| | - J A Soucy
- Dept. of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, J.B. Winsloewsvej 25-2, 5000 Odense C, Denmark
| | - A A Kabiljagic
- Dept. of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, J.B. Winsloewsvej 25-2, 5000 Odense C, Denmark
| | - K Skjoedt
- Dept. of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, J.B. Winsloewsvej 25-2, 5000 Odense C, Denmark
| | - J H Graversen
- Dept. of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, J.B. Winsloewsvej 25-2, 5000 Odense C, Denmark
| | - M L Henriksen
- Dept. of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, J.B. Winsloewsvej 25-2, 5000 Odense C, Denmark
| | - S W K Hansen
- Dept. of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, J.B. Winsloewsvej 25-2, 5000 Odense C, Denmark.
| |
Collapse
|
3
|
Pilely K, Nielsen SB, Draborg A, Henriksen ML, Hansen SWK, Skriver L, Mørtz E, Lund RR. A novel approach to evaluate ELISA antibody coverage of host cell proteins-combining ELISA-based immunocapture and mass spectrometry. Biotechnol Prog 2020; 36:e2983. [PMID: 32087048 PMCID: PMC7507178 DOI: 10.1002/btpr.2983] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2019] [Revised: 01/28/2020] [Accepted: 02/17/2020] [Indexed: 11/18/2022]
Abstract
Monitoring host cell proteins (HCPs) is one of the most important analytical requirements in production of recombinant biopharmaceuticals to ensure product purity and patient safety. Enzyme‐linked immunosorbent assay (ELISA) is the standard method for monitoring HCP clearance. It is important to validate that the critical reagent of an ELISA, the HCP antibody, covers a broad spectrum of the HCPs potentially present in the purified drug substance. Current coverage methods for assessing HCP antibody coverage are based on 2D‐Western blot or immunoaffinity‐purification combined with 2D gel electrophoresis and have several limitations. In the present study, we present a novel coverage method combining ELISA‐based immunocapture with protein identification by liquid chromatography–tandem mass spectrometry (LC–MS/MS): ELISA‐MS. ELISA‐MS is used to accurately determine HCP coverage of an early process sample by three commercially available anti‐Escherichia coli HCP antibodies, evading the limitations of current methods for coverage analysis, and taking advantage of the benefits of MS analysis. The results obtained comprise a list of individual HCPs covered by each HCP antibody. The novel method shows high sensitivity, high reproducibility, and enables tight control of nonspecific binding through inclusion of a species‐specific isotype control antibody. We propose that ELISA‐MS will be a valuable supplement to existing coverage methods or even a replacement. ELISA‐MS will increase the possibility of selecting the best HCP ELISA, thus improving HCP surveillance and resulting in a final HCP profile with the lowest achievable risk. Overall, this will be beneficial to both the pharmaceutical industry and patient safety.
Collapse
Affiliation(s)
| | | | - Anette Draborg
- Alphalyse A/S, Odense, Denmark.,Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark
| | - Maiken L Henriksen
- Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark
| | - Søren W K Hansen
- Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark
| | | | | | | |
Collapse
|
4
|
Smedbråten J, Sagedal S, Åsberg A, Hartmann A, Rollag H, Mjøen G, Fagerland MW, Hansen SWK, Mollnes TE, Thiel S. Collectin Liver 1 and Collectin Kidney 1 of the Lectin Complement Pathway Are Associated With Mortality After Kidney Transplantation. Am J Transplant 2017; 17:265-271. [PMID: 27341702 DOI: 10.1111/ajt.13933] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2016] [Revised: 06/16/2016] [Accepted: 06/16/2016] [Indexed: 01/25/2023]
Abstract
Kidney transplanted patients still have significantly higher mortality compared with the general population. The innate immune system may play an important role during periods, with suppression of the adaptive immune system. In the present study, two soluble pattern recognition molecules of the innate immune system were investigated, collectin liver 1 (CL-L1) and collectin kidney 1 (CL-K1). Potential associations of their pretransplant levels and long-term graft and recipient survival were examined. The levels of CL-L1 and CL-K1 were measured at the time of transplantation in 382 patients (≥17 years) transplanted in 2000-2001. The cohort was subsequently followed until December 31, 2014. Data on patient and graft survival were obtained from the Norwegian Renal Registry. Both high CL-L1 (≥376 ng/mL) and high CL-K1 (≥304 ng/mL) levels were significantly associated with overall mortality in multivariate Cox analyses with hazard ration (HR) 1.50, 95% confidence interval (CI) 1.09-2.07, p = 0.013 and HR 1.43, 95% CI 1.02-1.99, p = 0.038, respectively. Moreover, high CL-K1 levels were significantly associated with cardiovascular mortality. No association between measured biomarkers and death-censored graft loss was found. Finally, there was a significant correlation between these two collectins, r = 0.83 (95% CI 0.80-0.86). In conclusion, CL-L1 and CL-K1 were significantly associated with mortality in kidney transplant recipients.
Collapse
Affiliation(s)
- J Smedbråten
- Department of Nephrology, Ullevål Oslo University Hospital, Oslo, Norway.,Faculty of Medicine, University of Oslo, Oslo, Norway
| | - S Sagedal
- Department of Nephrology, Ullevål Oslo University Hospital, Oslo, Norway
| | - A Åsberg
- Department of Transplant Medicine, Rikshospitalet Oslo University Hospital, Oslo, Norway.,Norwegian Renal Registry, Oslo University Hospital, Oslo, Norway.,School of Pharmacy, University of Oslo, Oslo, Norway
| | - A Hartmann
- Faculty of Medicine, University of Oslo, Oslo, Norway.,Department of Transplant Medicine, Rikshospitalet Oslo University Hospital, Oslo, Norway
| | - H Rollag
- Faculty of Medicine, University of Oslo, Oslo, Norway.,Department of Microbiology, Rikshospitalet Oslo University Hospital, Oslo, Norway
| | - G Mjøen
- Department of Transplant Medicine, Rikshospitalet Oslo University Hospital, Oslo, Norway
| | - M W Fagerland
- Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo, Norway
| | - S W K Hansen
- Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark
| | - T E Mollnes
- Faculty of Medicine, University of Oslo, Oslo, Norway.,Department of Immunology, Oslo University Hospital Rikshospitalet and K. G. Jebsen IRC, University of Oslo, Oslo, Norway.,Research Laboratory, Nordland Hospital, Bodø, Norway.,Faculty of Health Sciences, K. G. Jebsen TREC, University of Tromsø, Tromsø, Norway.,Center of Molecular Inflammation Research, Norwegian University of Science and Technology, Trondheim, Norway
| | - S Thiel
- Department of Biomedicine, Aarhus University, Aarhus, Denmark
| |
Collapse
|
5
|
Hansen JS, Nørgaard AW, Koponen IK, Sørli JB, Paidi MD, Hansen SWK, Clausen PA, Nielsen GD, Wolkoff P, Larsen ST. Limonene and its ozone-initiated reaction products attenuate allergic lung inflammation in mice. J Immunotoxicol 2016; 13:793-803. [DOI: 10.1080/1547691x.2016.1195462] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Affiliation(s)
- Jitka S. Hansen
- The National Research Centre for the Working Environment, Copenhagen, Denmark
| | - Asger W. Nørgaard
- The National Research Centre for the Working Environment, Copenhagen, Denmark
| | - Ismo K. Koponen
- The National Research Centre for the Working Environment, Copenhagen, Denmark
| | - Jorid B. Sørli
- The National Research Centre for the Working Environment, Copenhagen, Denmark
| | - Maya D. Paidi
- The National Research Centre for the Working Environment, Copenhagen, Denmark
| | - Søren W. K. Hansen
- Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark
| | - Per Axel Clausen
- The National Research Centre for the Working Environment, Copenhagen, Denmark
| | - Gunnar D. Nielsen
- The National Research Centre for the Working Environment, Copenhagen, Denmark
| | - Peder Wolkoff
- The National Research Centre for the Working Environment, Copenhagen, Denmark
| | - Søren Thor Larsen
- The National Research Centre for the Working Environment, Copenhagen, Denmark
| |
Collapse
|